Projects per year
Abstract
Burkholderia cepacia complex is a cause of serious lung infections in people with cystic fibrosis, exhibiting extremely high levels of antimicrobial resistance. These infections are difficult to treat and are associated with high morbidity and mortality. With a notable lack of new antibiotic classes currently in development, exploring alternative antimicrobial strategies for Burkholderia cepacia complex is crucial. One potential alternative seeing renewed interest is the use of bacteriophage (phage) therapy. This review summarises what is currently known about Burkholderia cepacia complex in cystic fibrosis, as well as challenges and insights for using phages to treat Burkholderia cepacia complex lung infections.
Original language | English |
---|---|
Article number | 1476041 |
Number of pages | 12 |
Journal | Frontiers in Microbiology |
Volume | 15 |
Early online date | 18 Oct 2024 |
DOIs | |
Publication status | Published - 2024 |
Fingerprint
Dive into the research topics of 'Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: perspectives and challenges'. Together they form a unique fingerprint.Projects
- 2 Active
-
Priority Driven Childhood Respiratory Research
Stick, S. (Investigator 01)
NHMRC National Health and Medical Research Council
1/01/22 → 31/12/26
Project: Research
-
The microbial ecology of the upper airways in children
Nicol, M. (Investigator 01)
NHMRC National Health and Medical Research Council
1/01/20 → 31/12/25
Project: Research